Cargando…

Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study

BACKGROUND: Adjuvant bisphosphonates (BPs) are recommended as part of routine early breast cancer treatment for many postmenopausal (PM) women within the past year. There is a paucity of ‘real world’ data on compliance and patient satisfaction with oral BPs in this population. The aim of our study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, C., Martin, C., Winter, M.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429539/
https://www.ncbi.nlm.nih.gov/pubmed/30937280
http://dx.doi.org/10.1016/j.jbo.2019.100226
_version_ 1783405617934761984
author Wilson, C.
Martin, C.
Winter, M.C.
author_facet Wilson, C.
Martin, C.
Winter, M.C.
author_sort Wilson, C.
collection PubMed
description BACKGROUND: Adjuvant bisphosphonates (BPs) are recommended as part of routine early breast cancer treatment for many postmenopausal (PM) women within the past year. There is a paucity of ‘real world’ data on compliance and patient satisfaction with oral BPs in this population. The aim of our study was to investigate patient reported compliance and toxicity of these drugs in a retrospective cohort study. PATIENTS AND METHODS: 413 patient were identified as receiving adjuvant oral BPs as part of their breast cancer treatment in the past 12 months from five NHS hospitals. The validated Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q) was sent to all suitable patients (n = 389). RESULTS: 295 (76%) of patients responded. Average age was median (range) 67 (35–89). The majority of patients had T1 (52%), N0 (61%) grade 2 (58%) ER positive (87%), HER2 negative (84%) breast cancer and were PM at diagnosis of breast cancer (93%). All patients had been prescribed at least 1 month of oral ibandronate 50 mg daily. Review of items rated on the 7-point scale (1 = very dissatisfied to 7 = very satisfied), the mean item scores ranged from 5.0 (lowest) for time required to take oral BPs, to 6.1 (highest) for how easy it is to remember to take the medication. <10% of patients were extremely bothered by heartburn or stomach upset. 16% of responders stopped oral BPs with 10% of those converting onto IV BPs. CONCLUSIONS: Prevalence of severe side effects in a ‘real world’ population of PM women receiving adjuvant BPs is low and these drugs are generally well accepted and tolerated by patients.
format Online
Article
Text
id pubmed-6429539
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-64295392019-04-01 Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study Wilson, C. Martin, C. Winter, M.C. J Bone Oncol Research Article BACKGROUND: Adjuvant bisphosphonates (BPs) are recommended as part of routine early breast cancer treatment for many postmenopausal (PM) women within the past year. There is a paucity of ‘real world’ data on compliance and patient satisfaction with oral BPs in this population. The aim of our study was to investigate patient reported compliance and toxicity of these drugs in a retrospective cohort study. PATIENTS AND METHODS: 413 patient were identified as receiving adjuvant oral BPs as part of their breast cancer treatment in the past 12 months from five NHS hospitals. The validated Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q) was sent to all suitable patients (n = 389). RESULTS: 295 (76%) of patients responded. Average age was median (range) 67 (35–89). The majority of patients had T1 (52%), N0 (61%) grade 2 (58%) ER positive (87%), HER2 negative (84%) breast cancer and were PM at diagnosis of breast cancer (93%). All patients had been prescribed at least 1 month of oral ibandronate 50 mg daily. Review of items rated on the 7-point scale (1 = very dissatisfied to 7 = very satisfied), the mean item scores ranged from 5.0 (lowest) for time required to take oral BPs, to 6.1 (highest) for how easy it is to remember to take the medication. <10% of patients were extremely bothered by heartburn or stomach upset. 16% of responders stopped oral BPs with 10% of those converting onto IV BPs. CONCLUSIONS: Prevalence of severe side effects in a ‘real world’ population of PM women receiving adjuvant BPs is low and these drugs are generally well accepted and tolerated by patients. Elsevier 2019-02-19 /pmc/articles/PMC6429539/ /pubmed/30937280 http://dx.doi.org/10.1016/j.jbo.2019.100226 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Wilson, C.
Martin, C.
Winter, M.C.
Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
title Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
title_full Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
title_fullStr Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
title_full_unstemmed Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
title_short Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
title_sort compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. a cross sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429539/
https://www.ncbi.nlm.nih.gov/pubmed/30937280
http://dx.doi.org/10.1016/j.jbo.2019.100226
work_keys_str_mv AT wilsonc complianceandpatientreportedtoxicityfromoraladjuvantbisphosphonatesinpatientswithearlybreastcanceracrosssectionalstudy
AT martinc complianceandpatientreportedtoxicityfromoraladjuvantbisphosphonatesinpatientswithearlybreastcanceracrosssectionalstudy
AT wintermc complianceandpatientreportedtoxicityfromoraladjuvantbisphosphonatesinpatientswithearlybreastcanceracrosssectionalstudy